2Wiley SR, Sehooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995,3 : 673-682.
3Pitti RM. Marstem SA,Ruppert S,et al. Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor cytokine family[J]. J Bio Chem, 1996,271 : 12687- 12690.
4Pan GH, Reiner Gentz,Reinhard Ebner, et al. The receptor for the cytotxic ligand TRAIL. Science, 1997,276 : 111-113.
5Walczak H, Mariapia A, Pamela J, et al. TRAIL-R2:a novel apoptosis-mediating receptor for TRAIL. EMBO J, 1997, 16:5386 - 5397.
6Degli-Esposti, Anna Ghelli, Bruna Benelli, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis,yet retains an incomplete death domain. Immunity, 1997,7:813-820.
7Liang GP, Yang SM, Luo XD. The research progress of trail receptors and their signal transduction[J]. Foreign Med Sci (Clin Biochem Lab Med Foreign Med Sci), 2001,22(3) : 119-120.
8Pritzker LB,Seatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell, 2004, 15:2834-2841.
9Zauli G, Rimondi E, Nicolin V, et al. TNF-related apoptosis inducing ligand(TRAIL) blocks octeoclastic differentiation induced by RANKL+MCSF. Blood, 2004,104: 2044-2050.
2Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer[J].Mol Cells. 2003,15(3) :283-293.
3Liu XS, Zhu Y, Han WN, et al. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1 and DcR2[J]. Hybrid hybridomics. 2003,22(2):121-123.
4Krieg A, Krieg T,Wenzel M, et al. TRAIL-beta and TRAIL-gama:two novel splice variants of the human TNF-related apoptosis inducing ligand (TRAIL) without apoptosis potential[J]. Br J Cancer. 2003,88(6) :918-927.
5Takeda K, Yarnaguchi N, Akiba H, et al. Induction of Tumorspecific T Cell Immunity by Anti-DR5 Antibody Therapy[J]. The Journal of Experimental Medidne. 2004,199(4): 437-448.
6Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes [J].Cancer Res,2000,60(3) :553-559.
7Chawla-Sarkar M, Bae SI, Reu FJ, et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo-2L/TRAIL- induced apoptosis[J]. Cell Death Differ, 2004,11 (8) :915-923.
8Wiley SR, Schooey K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity,1995;3(6):673.
9Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast.Can J Surg,1991;3414(4):349.
10Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science,1997;277(5327):818.
1Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995,3 (6) : 673-682.
2Yoldas B, Ozer C, Ozen O, et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck, 2011,33(9) : 1278-1284.
3Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer, 2004,109 (5) : 786-792.
4Trarbach T, Moehler M, Heinemann V, et al. Phase 11 trial of mapatumumab, a fully human agonistie monoelonal antibodythat targets and activates the tumour necrosis factor apoptosis- inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer, 2010,102(3) :506-512.
5Jiang M, Liu Z, Xiang Y, et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 2011,11:54.
6Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res, 2005,65 ( 11 ) : 4902-4908.
7Nikrad M, Johnson T, Puthalalath H, et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther, 2005,4(3) :443-449.
8Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res, 2007,13 ( 11 ) : 3403-3412.
9Shim SH, Lee CT, Hun Hah J, et al. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of El-deleted adenovirus carrying TRAIL in head and neck aquamous cell carcinoma. Cancer Sci, 2010,101 (2) :482-487.
10Elord HA, Fan S, Muller S, et al. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One, 2010,5(8) :e12178.
